Published in Am J Infect Dis on January 01, 2006
The Mycobacterium bovis bacille Calmette-Guerin phagosome proteome. Mol Cell Proteomics (2009) 0.98
Drugs of abuse and HIV infection/replication: implications for mother-fetus transmission. Life Sci (2010) 0.87
Morphine and galectin-1 modulate HIV-1 infection of human monocyte-derived macrophages. J Immunol (2012) 0.80
Serum proteomic analysis reveals high frequency of haptoglobin deficiency and elevated thyroxine level in heroin addicts. PLoS One (2014) 0.75
Proteomics, biomarkers, and HIV-1: A current perspective. Proteomics Clin Appl (2015) 0.75
Heroin inhibits HIV-restriction miRNAs and enhances HIV infection of macrophages. Front Microbiol (2015) 0.75
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem (1987) 281.19
A method for the quantitative recovery of protein in dilute solution in the presence of detergents and lipids. Anal Biochem (1984) 19.70
Femtomole sequencing of proteins from polyacrylamide gels by nano-electrospray mass spectrometry. Nature (1996) 9.36
The neuropathogenesis of AIDS. Nat Rev Immunol (2005) 6.54
Immune function of astrocytes. Glia (2001) 4.05
Mass spectrometric identification of proteins from silver-stained polyacrylamide gel: a method for the removal of silver ions to enhance sensitivity. Electrophoresis (1999) 3.71
Validation and development of fluorescence two-dimensional differential gel electrophoresis proteomics technology. Proteomics (2001) 3.02
The role of macrophage/microglia and astrocytes in the pathogenesis of three neurologic disorders: HIV-associated dementia, Alzheimer disease, and multiple sclerosis. J Neurol Sci (2002) 2.53
Cytoskeleton association and virion incorporation of the human immunodeficiency virus type 1 Vif protein. J Virol (1996) 2.30
Human immunodeficiency virus (HIV) proteins in neuropathogenesis of HIV dementia. J Infect Dis (2002) 2.19
Cells of the central nervous system as targets and reservoirs of the human immunodeficiency virus. Virus Res (2005) 2.09
Astrocytes: HIV cellular reservoirs and important participants in neuropathogenesis. AIDS (1999) 1.84
Molecular basis for interactions of HIV and drugs of abuse. J Acquir Immune Defic Syndr (2002) 1.83
The neuropathogenesis of HIV-1 infection. J Leukoc Biol (1994) 1.83
Proteomic characterization of wheat amyloplasts using identification of proteins by tandem mass spectrometry. Proteomics (2002) 1.60
Acceleration of HIV dementia with methamphetamine and cocaine. J Neurovirol (2001) 1.56
Cathepsins and compartmentalization in antigen presentation. Curr Opin Immunol (2000) 1.55
CLC chloride channels and transporters. Curr Opin Neurobiol (2005) 1.53
HIV-1 gp120 and chemokines activate ion channels in primary macrophages through CCR5 and CXCR4 stimulation. Proc Natl Acad Sci U S A (2000) 1.53
Galectins as inflammatory mediators. Glycoconj J (2004) 1.52
Glial neuronal signaling in the central nervous system. FASEB J (2003) 1.51
Comprehensive proteomics in yeast using chromatographic fractionation, gas phase fractionation, protein gel electrophoresis, and isoelectric focusing. Proteomics (2005) 1.45
Investigative proteomics: identification of an unknown plant virus from infected plants using mass spectrometry. J Am Soc Mass Spectrom (2003) 1.38
Trans-activation of HIV-1 LTR-directed gene expression by tat requires protein kinase C. EMBO J (1990) 1.29
Characterization of the MHC class I cross-presentation pathway for cell-associated antigens by human dendritic cells. Blood (2003) 1.29
Highly productive infection with pseudotyped human immunodeficiency virus type 1 (HIV-1) indicates no intracellular restrictions to HIV-1 replication in primary human astrocytes. J Virol (2001) 1.28
Galectin-1 acts as a soluble host factor that promotes HIV-1 infectivity through stabilization of virus attachment to host cells. J Immunol (2005) 1.26
HIV infection among persons who inject illicit drugs: problems and prospects. J Acquir Immune Defic Syndr (1988) 1.25
Proteome analysis: biological assay or data archive? Electrophoresis (1998) 1.23
Mechanics of vimentin intermediate filaments. J Muscle Res Cell Motil (2002) 1.22
Phosphorylation of HIV-1 gag proteins by protein kinase C. J Biol Chem (1993) 1.17
Molecular and cellular mechanisms of neuronal cell death in HIV dementia. Neurotox Res (2005) 1.15
Galectin-1 receptors in different cell types. J Biomed Sci (2005) 1.12
Galectin-1: a bifunctional regulator of cellular proliferation. Glycoconj J (2004) 1.08
HIV-infection of the central nervous system: the tightrope walk of innate immunity. Mol Immunol (2005) 1.04
Real-time PCR assay for quantitative mismatch detection. Biotechniques (2003) 1.03
In vivo and in vitro infection of the astrocyte by HIV-1. Adv Neuroimmunol (1994) 1.01
HIV-1 infectivity and host range modification by cathepsin D present in human vaginal secretions. AIDS (1999) 1.00
Human immunodeficiency virus type 1 protease microinjected into cultured human skin fibroblasts cleaves vimentin and affects cytoskeletal and nuclear architecture. J Cell Sci (1991) 0.99
Novel pathway of human immunodeficiency virus type 1 uptake and release in astrocytes. Virology (2006) 0.99
Site-specific phosphorylation of the human immunodeficiency virus type-1 Rev protein accelerates formation of an efficient RNA-binding conformation. Biochemistry (1997) 0.97
Cleavage of vimentin by different retroviral proteases. Arch Biochem Biophys (2000) 0.94
Intermediate filament assembly and stability in vitro: effect and implications of the removal of head and tail domains of vimentin by the human immunodeficiency virus type 1 protease. Cell Biol Int Rep (1990) 0.94
Intracellular chloride channels: critical mediators of cell viability and potential targets for cancer therapy. Curr Pharm Des (2005) 0.91
Immunological assays for chemokine detection in in-vitro culture of CNS cells. Biol Proced Online (2003) 0.90
Proteomics analysis of human astrocytes expressing the HIV protein Tat. Brain Res Mol Brain Res (2005) 0.90
Fully functional, naturally occurring and C-terminally truncated variant human immunodeficiency virus (HIV) Vif does not bind to HIV Gag but influences intermediate filament structure. J Gen Virol (2001) 0.88
A human milk factor susceptible to cathepsin D inhibitors enhances human immunodeficiency virus type 1 infectivity and allows virus entry into a mammary epithelial cell line. J Virol (2000) 0.88
Amino-terminal polypeptides of vimentin are responsible for the changes in nuclear architecture associated with human immunodeficiency virus type 1 protease activity in tissue culture cells. Mol Biol Cell (2001) 0.85
Protein kinase Calpha and epsilon small-molecule targeted therapeutics: a new roadmap to two Holy Grails in drug discovery? Expert Rev Anticancer Ther (2006) 0.83
Degradation of cytoskeletal proteins by the human immunodeficiency virus type 1 protease. Cell Biol Int Rep (1992) 0.82
Antiviral drugs from the nucleoside analog family block volume-activated chloride channels. Mol Med (1995) 0.82
Engagement of CD28 modulates CXC chemokine receptor 4 surface expression in both resting and CD3-stimulated CD4+ T cells. J Immunol (2000) 0.82
Current concepts in human immunodeficiency virus infection and AIDS. Clin Diagn Lab Immunol (1999) 0.81
In vitro phosphorylation of human immunodeficiency virus type 1 Tat protein by protein kinase C: evidence for the phosphorylation of amino acid residue serine-46. Arch Biochem Biophys (1996) 0.81
Assessment by flow cytometry of peripheral blood leukocyte enzymatic activities in HIV patients. J Immunol Methods (2001) 0.79
Gene expression of angiogenic factors correlates with metastatic potential of prostate cancer cells. Cancer Res (2004) 1.44
Magnetic nanoformulation of azidothymidine 5'-triphosphate for targeted delivery across the blood-brain barrier. Int J Nanomedicine (2010) 1.31
Nanotechnology approach for drug addiction therapy: gene silencing using delivery of gold nanorod-siRNA nanoplex in dopaminergic neurons. Proc Natl Acad Sci U S A (2009) 1.27
Interactive role of human immunodeficiency virus type 1 (HIV-1) clade-specific Tat protein and cocaine in blood-brain barrier dysfunction: implications for HIV-1-associated neurocognitive disorder. J Neurovirol (2010) 1.16
MMP-9 gene silencing by a quantum dot-siRNA nanoplex delivery to maintain the integrity of the blood brain barrier. Brain Res (2009) 1.12
Bioconjugated quantum rods as targeted probes for efficient transmigration across an in vitro blood-brain barrier. Bioconjug Chem (2008) 1.11
Cocaine modulates dendritic cell-specific C type intercellular adhesion molecule-3-grabbing nonintegrin expression by dendritic cells in HIV-1 patients. J Immunol (2005) 1.11
Methamphetamine modulates gene expression patterns in monocyte derived mature dendritic cells: implications for HIV-1 pathogenesis. Mol Diagn Ther (2006) 1.11
HIV-1 Tat upregulates expression of histone deacetylase-2 (HDAC2) in human neurons: implication for HIV-associated neurocognitive disorder (HAND). Neurochem Int (2011) 1.09
Morphine modulates chemokine gene regulation in normal human astrocytes. Clin Immunol (2005) 1.09
Morphine regulates gene expression of alpha- and beta-chemokines and their receptors on astroglial cells via the opioid mu receptor. J Immunol (2002) 1.08
Differential effects of HIV type 1 clade B and clade C Tat protein on expression of proinflammatory and antiinflammatory cytokines by primary monocytes. AIDS Res Hum Retroviruses (2009) 1.06
Human synaptic plasticity gene expression profile and dendritic spine density changes in HIV-infected human CNS cells: role in HIV-associated neurocognitive disorders (HAND). PLoS One (2013) 1.05
Genomic Analysis Highlights the Role of the JAK-STAT Signaling in the Anti-proliferative Effects of Dietary Flavonoid-'Ashwagandha' in Prostate Cancer Cells. Evid Based Complement Alternat Med (2008) 1.04
Morphine exacerbates HIV-1 viral protein gp120 induced modulation of chemokine gene expression in U373 astrocytoma cells. Curr HIV Res (2005) 1.00
Enhancing the delivery of anti retroviral drug "Saquinavir" across the blood brain barrier using nanoparticles. Curr HIV Res (2010) 0.99
Proteomic analysis of the effects of cocaine on the enhancement of HIV-1 replication in normal human astrocytes (NHA). Brain Res (2006) 0.99
Differential regulation of indoleamine-2,3-dioxygenase (IDO) by HIV type 1 clade B and C Tat protein. AIDS Res Hum Retroviruses (2009) 0.99
The dietary bioflavonoid, quercetin, selectively induces apoptosis of prostate cancer cells by down-regulating the expression of heat shock protein 90. Prostate (2008) 0.93
Proteomic analyses of methamphetamine (METH)-induced differential protein expression by immature dendritic cells (IDC). Biochim Biophys Acta (2007) 0.93
Ashwagandha (Withania somnifera) reverses β-amyloid1-42 induced toxicity in human neuronal cells: implications in HIV-associated neurocognitive disorders (HAND). PLoS One (2013) 0.93
AZT 5'-triphosphate nanoformulation suppresses human immunodeficiency virus type 1 replication in peripheral blood mononuclear cells. J Neurovirol (2009) 0.92
Human immunodeficiency virus type 1 clade B and C Tat differentially induce indoleamine 2,3-dioxygenase and serotonin in immature dendritic cells: Implications for neuroAIDS. J Neurovirol (2010) 0.92
Drug abuse and neuropathogenesis of HIV infection: role of DC-SIGN and IDO. J Neuroimmunol (2004) 0.92
Preparation of quantum dot/drug nanoparticle formulations for traceable targeted delivery and therapy. Theranostics (2012) 0.91
HIV-1 gp120 induces antioxidant response element-mediated expression in primary astrocytes: role in HIV associated neurocognitive disorder. Neurochem Int (2011) 0.90
Gene Silencing of Human Neuronal Cells for Drug Addiction Therapy using Anisotropic Nanocrystals. Theranostics (2012) 0.90
Human immunodeficiency virus type 1 clade B and C gp120 differentially induce neurotoxin arachidonic acid in human astrocytes: implications for neuroAIDS. J Neurovirol (2011) 0.90
Tissue inhibitor of metalloproteinase-1 modulates allergic lung inflammation in murine asthma. Clin Immunol (2008) 0.88
Modulation of the proteome of peripheral blood mononuclear cells from HIV-1-infected patients by drugs of abuse. J Clin Immunol (2009) 0.88
Overexpression of MMP-9 contributes to invasiveness of prostate cancer cell line LNCaP. Immunol Invest (2011) 0.88
Nanoparticle based galectin-1 gene silencing, implications in methamphetamine regulation of HIV-1 infection in monocyte derived macrophages. J Neuroimmune Pharmacol (2012) 0.87
Interactive Effects of Morphine on HIV Infection: Role in HIV-Associated Neurocognitive Disorder. AIDS Res Treat (2012) 0.86
Combinatorial cytotoxic effects of Curcuma longa and Zingiber officinale on the PC-3M prostate cancer cell line. J Basic Clin Physiol Pharmacol (2012) 0.85
HIV infection and drugs of abuse: role of acute phase proteins. J Neuroinflammation (2013) 0.85
RNAi-directed inhibition of DC-SIGN by dendritic cells: prospects for HIV-1 therapy. AAPS J (2005) 0.84
Well-defined degradable cationic polylactide as nanocarrier for the delivery of siRNA to silence angiogenesis in prostate cancer. Adv Healthc Mater (2012) 0.84
Methamphetamine and HIV-1 gp120 effects on lipopolysaccharide stimulated matrix metalloproteinase-9 production by human monocyte-derived macrophages. Immunol Invest (2011) 0.84
A global perspective on HIV/AIDS. Science (2012) 0.83
Proteomic analyses of the effects of drugs of abuse on monocyte-derived mature dendritic cells. Immunol Invest (2009) 0.83
Single nucleotide polymorphisms (SNPs) in key cytokines may modulate food allergy phenotypes. Eur Food Res Technol (2012) 0.81
Prostate-specific antigen modulates the expression of genes involved in prostate tumor growth. Neoplasia (2005) 0.81
SARS coronavirus spike protein-induced innate immune response occurs via activation of the NF-kappaB pathway in human monocyte macrophages in vitro. Virus Res (2009) 0.81
Transmitted antiretroviral drug resistance in the men who have sex with men HIV patient cohort, Beijing, China, 2008-2011. Viral Immunol (2014) 0.81
Chronic constriction injury-induced nociception is relieved by nanomedicine-mediated decrease of rat hippocampal tumor necrosis factor. Pain (2015) 0.81
Implications of ER stress, the unfolded protein response, and pro- and anti-apoptotic protein fingerprints in human monocyte-derived dendritic cells treated with alcohol. Alcohol Clin Exp Res (2010) 0.80
Morphine and galectin-1 modulate HIV-1 infection of human monocyte-derived macrophages. J Immunol (2012) 0.80
MicroRNA: implications in HIV, a brief overview. J Neurovirol (2011) 0.79
Chemopreventive potential of an ethyl acetate fraction from Curcuma longa is associated with upregulation of p57(kip2) and Rad9 in the PC-3M prostate cancer cell line. Asian Pac J Cancer Prev (2012) 0.79
Photopheresis in HIV-1 infected patients utilizing benzoporphyrin derivative (BPD) verteporfin and light. Curr HIV Res (2008) 0.78
Upregulation of serotonin transporter by alcohol in human dendritic cells: possible implication in neuroimmune deregulation. Alcohol Clin Exp Res (2009) 0.78
Prostate-Specific Antigen Modulates the Expression of Genes Involved in Prostate Tumor Growth. Neoplasia (2005) 0.78
Two step procedure for purification of enzymatically active prostate-specific antigen from seminal plasma. J Chromatogr B Analyt Technol Biomed Life Sci (2004) 0.77
New Insights into the Disease Progression Control Mechanisms by Comparing Long-Term-Nonprogressors versus Normal-Progressors among HIV-1-Positive Patients Using an Ion Current-Based MS1 Proteomic Profiling. J Proteome Res (2015) 0.76
Proteomic Approach to Evaluate Mechanisms That Contribute to Food Allergenicity: Comparative 2D-DIGE Analysis of Radioallergosorbent Test Positive and Negative Patients. Int J Proteomics (2011) 0.75
Nanotherapeutics: emerging competent technology in neuroAIDS and CNS drug delivery. Nanomedicine (Lond) (2012) 0.75
Serum interferon inhibitor declines in patients with HIV-1 infection after a change in antiretroviral therapy. Immunol Invest (2003) 0.75
Quantum rods as nanocarriers of gene therapy. Drug Deliv (2012) 0.75
Cell cycle checkpoints and pathogenesis of HIV-1 infection: a brief overview. J Basic Clin Physiol Pharmacol (2015) 0.75
Nanotherapeutic approach for opiate addiction using DARPP-32 gene silencing in an animal model of opiate addiction. J Neuroimmune Pharmacol (2015) 0.75